Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication
Regular injections are needed to achieve this
Its pivotal trial enrolled 816 participants and met its primary efficacy endpoint, supporting FDA approval in 2010 with documented visceral fat reductions of roughly 15-18% over 26 weeks
GIP receptor activation at low doses supports mitochondrial function in adipose tissue and may contribute to improved fatty acid metabolism independent of the dramatic appetite suppression seen at full doses
Most patients find their optimal maintenance dose somewhere between 5 mg and 15 mg weekly
Prepaid Your reservation will be confirmed with an advance payment of 50% of the total cost of the reserved service
